3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Venous Thromboembolism
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Hemorrhage
1
Interventions
Epoetin Alfa
27
Darbepoetin alfa
13
Cytarabine
9
Dalteparin
8
Rivaroxaban
7
Daunorubicin
7
apixaban
6
Etoposide
6
Methotrexate
5
Idarubicin
5
Heparin, Low-Molecular-Weight
5
Cyclophosphamide
5
emicizumab
4
Tinzaparin
4
Thioguanine
4
Mitoxantrone
4
Granulocyte Colony-Stimulating Factor
4
Filgrastim
4
Enoxaparin
4
pegfilgrastim
3
hetrombopag
3
epoetin beta
3
Saline Solution
3
Radiotherapy
3
Hydrocortisone
3
Erythropoietin
3
Dexamethasone
3
Aspirin
3
Asparaginase
3
telapristone acetate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
N(4)-oleylcytosine arabinoside
×
Classical hematology
×
Clear all
NCT05198960
2026-03-20
AVAJAK
University Hospital, Brest
Phase 3
Recruiting
1,308 enrolled